Hadlima (adalimumab) is a biologic medicine that helps the pain and swelling of arthritis.
Hadlima works by blocking Tumor Necrosis Factor (TNF), a type of signalling protein (called a cytokine), that is involved in systemic inflammation. Hadlima belongs to a class of similar medications called Anti-Tumor Necrosis Factor agents.
Hadlima may be prescribed in combination with other rheumatology medications like methotrexate.
Hadlima is a type of medicine that is called a biosimilar. A biosimilar is a type of biologic medication that is designed to be identical to an existing biologic medication, but is created using a different process.
Hadlima is a biosimilar of Humira. Both medications are known by the same generic name: adalimumab. Biosimilars are often cheaper than the original medication.
Hadlima is available as a subcutaneous (under the skin) injection in one of two forms that can be taken at home: as a pre-filled syringe, and as an autoinjector (pen).
Hadlima usually takes about 2 weeks before patients start to feel its effects. It may take 12 weeks to feel the effect of this medicine.
The manufacturer of Hadlima offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms
Important Tests and Risks
Drug Identification Number (DIN)